Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05105152
Other study ID # PLAT-08
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 29, 2021
Est. completion date January 31, 2041

Study information

Verified date February 2024
Source Seattle Children's Hospital
Contact Adam Lamble, MD
Phone 206-986-2106
Email CBDCIntake@seattlechildrens.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date January 31, 2041
Est. primary completion date February 28, 2026
Accepts healthy volunteers No
Gender All
Age group N/A to 30 Years
Eligibility Inclusion Criteria: 1. Subject age = 30 years. The first three enrolled subjects must be = 18 years of age. 2. AML that expresses CD33 by flow cytometry and meets one of the below definitions: 1. For subjects who have previously received an allogeneic HCT, any evidence of AML re-emergence post HCT detectable by flow cytometry 2. First relapse of AML = 6 months of initial diagnosis 3. First relapse of AML > 6 months after initial diagnosis, with MRD of >0.1% by flow cytometry (MPF) after at least one re-induction (single cycle) attempt 4. Second or greater relapse AML 5. Refractory AML, defined as >1% leukemic cells determined by flow cytometry after 2 cycles of induction chemotherapy 3. Able to tolerate apheresis, or subject with sufficient existing apheresis product or T cells for manufacturing investigational product. 4. Life expectancy = 8 weeks 5. Has an appropriate stem cell donor source identified 6. Lansky performance status score of = 50 for subjects <16 years of age or Karnofsky score = 50 for subjects = 16 years. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes of assessing performance status 7. If a subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of DARIC T cells, the subject must discontinue all anticancer agents and radiotherapy and, in the opinion of the investigator, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy: a. Chemotherapy and biologic agents: All chemotherapy and biologic therapy not specifically mentioned below must be discontinued = 7 days prior to enrollment, with the exception of intrathecal chemotherapy for which there is not a required washout period b. Must be = 30 days from last gemtuzumab ozogamicin dose. c. Steroid use: All corticosteroid therapy (unless physiologic replacement dosing) must be discontinued = 7 days prior to enrollment d. Tyrosine Kinase Inhibitor (TKI) use: All TKIs must be discontinued = 3 days prior to enrollment e. Hydroxyurea: must be discontinued = 1 day prior to enrollment. f. Gene Modified cellular therapy: i. must be at least 30 days from most recent gene modified cell therapy infusion and document no evidence of modified cells in the peripheral blood OR ii. must be at least 60 days from most recent gene modified cell therapy 8. Adequate organ function as indicated by: 1. Renal: Serum creatinine = 1.5 X the upper limit of normal (ULN) 2. Hepatic: Total bilirubin = 3 times ULN for age OR conjugated bilirubin = 2 mg/dL AND ALT (SGPT) = 5 times ULN 3. Cardiac: Shortening fraction = 28% OR ejection fraction = 50% as measured by echocardiogram 4. Respiratory: Oxygen saturation = 92% on room air without supplemental oxygen or mechanical ventilation 9. Laboratory values meet the following criteria: a. Subjects requiring apheresis: Absolute Lymphocyte Count (ALC) = 100 cells/uL b. Virology Testing negative within 3 months prior to enrollment, to include: i. HIV antigen & antibody ii. Hepatitis B surface antigen iii. Hepatitis C antibody OR if positive, Hepatitis C PCR is negative 10. If subject is of childbearing or child-fathering potential, must agree to use highly effective contraception from the time of initial consent through 12 months following the infusion of investigational product on this trial. 11. Subject and/or legally authorized representative has signed the Informed Consent Form for this study Exclusion Criteria: 1. Active malignancy other than acute myeloid leukemia 2. History of symptomatic non-AML CNS disease or ongoing symptomatic CNS disease requiring medical intervention, including paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder (subjects with non-febrile seizure disorder controlled on anti-epileptic medication and without seizure activity within 1 month are eligible). 3. CNS AML involvement that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and DARIC T cell infusion 4. If history of allogeneic stem cell transplant: active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment 5. Presence of active severe infection, defined as: i. positive blood culture within 48 hours of enrollment, OR ii. fever above 38.2° C, AND clinical signs of infection within 48 hours of enrollment 6. Primary immunodeficiency syndrome 7. Subject has received prior virotherapy 8. Pregnant or breastfeeding 9. Subject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow-up period, required if DARIC T cell therapy is administered 10. Presence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol 11. Considered by the investigator to be unable to tolerate a lymphodepleting regimen 12. Subject has a contraindication to receiving rapamycin

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SC-DARIC33
Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration

Locations

Country Name City State
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Seattle Children's Hospital 2seventy bio

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events associated with SC-DARIC33 cell product infusions will be assessed The type, frequency, severity, and duration of adverse events will be summarized 28 days post-infusion
Primary Ability to successfully manufacture SC-DARIC33 Measure of the number of successfully manufactured SC-DARIC33 products 28 days
Secondary Acute Myeloid Leukemia response to SC-DARIC in subjects with relapsed or refractory CD33+ myeloid leukemia will be assessed The efficacy of the SC-DARIC33 assessed based on the bone marrow aspirate testing following SC-DARIC infusion 28 days post-infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2